Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Goudsmit

Showing results (401-410 of 424) with videos related to

Pageof 43
Sort By:
Vaccine|May 12, 2009
Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse geneticsW Koudstaal, L Hartgroves, M Havenga, et al.
Nature Medicine|September 30, 1999
Ongoing HIV dissemination during HAARTZ Grossman, M Polis, M B Feinberg, et al.
Biotechnology and Bioengineering|June 3, 2008
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivityM J E Havenga, L Holterman, I Melis, et al.
AIDS (London, England)|January 12, 2001
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infectionH Putter, J M Prins, S Jurriaans, et al.
AIDS (London, England)|August 26, 1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapyG J Weverling, J M Lange, S Jurriaans, et al.
Cancer Gene Therapy|November 4, 2006
Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patientsE Brouwer, M J Havenga, O Ophorst, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptationsD W Notermans, F de Wolf, P Oudshoorn, et al.
AIDS Research and Human Retroviruses|August 1, 1998
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detectionP Ondoa, B Willems, K Fransen, et al.
Vaccine|January 26, 2007
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cellsG Marzio, E Kerkvliet, J A Bogaards, et al.
Science (New York, N.Y.)|November 29, 1996
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnoverK C Wolthers, G Bea, A Wisman, et al.
Pageof 43

Showing results (401-410 of 424) with videos related to

Sort By:
Pageof 43
Vaccine|May 12, 2009
Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse geneticsW Koudstaal, L Hartgroves, M Havenga, et al.
Nature Medicine|September 30, 1999
Ongoing HIV dissemination during HAARTZ Grossman, M Polis, M B Feinberg, et al.
Biotechnology and Bioengineering|June 3, 2008
Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivityM J E Havenga, L Holterman, I Melis, et al.
AIDS (London, England)|January 12, 2001
Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infectionH Putter, J M Prins, S Jurriaans, et al.
AIDS (London, England)|August 26, 1998
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapyG J Weverling, J M Lange, S Jurriaans, et al.
Cancer Gene Therapy|November 4, 2006
Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patientsE Brouwer, M J Havenga, O Ophorst, et al.
AIDS Research and Human Retroviruses|October 29, 2000
Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptationsD W Notermans, F de Wolf, P Oudshoorn, et al.
AIDS Research and Human Retroviruses|August 1, 1998
Evaluation of different V3 peptides in an enzyme immunoassay for specific HIV type 1 group O antibody detectionP Ondoa, B Willems, K Fransen, et al.
Vaccine|January 26, 2007
A replication-competent adenovirus assay for E1-deleted Ad35 vectors produced in PER.C6 cellsG Marzio, E Kerkvliet, J A Bogaards, et al.
Science (New York, N.Y.)|November 29, 1996
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnoverK C Wolthers, G Bea, A Wisman, et al.
Pageof 43